Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.

Autor: Pryma C; Department of Pathology, University of British Columbia, Vancouver, BC, Canada., Villamil C; Department of Pathology, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology, British Columbia Cancer Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 1H5, Canada., Gibb EA; Decipher Urological Cancers, Veracyte, Inc., Vancouver, BC, Canada., Oo HZ; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Seiler R; Department of Urology, University Hospital Bern, Bern, Switzerland., Contreras-Sanz A; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Douglas J; Department of Urology, University Hospital of Southampton, Hampshire, UK., Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Wang G; Department of Pathology, University of British Columbia, Vancouver, BC, Canada. gang.wang1@bccancer.bc.ca.; Department of Pathology, British Columbia Cancer Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 1H5, Canada. gang.wang1@bccancer.bc.ca.

Publikováno v: Virchows Archiv : an international journal of pathology [Virchows Arch] 2022 Sep; Vol. 481 (3), pp. 397-403. Date of Electronic Publication: 2022 May 25.

Involvement of Mast-Cell-Tryptase- and Protease-Activated Receptor 2-Mediated Signaling and Urothelial Barrier Dysfunction with Reduced Uroplakin II Expression in Bladder Hyperactivity Induced by Chronic Bladder Ischemia in the Rat.

Autor: Akaihata H; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Matsuoka K; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Hata J; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Harigane Y; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Yaginuma K; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Endo Y; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Imai H; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Matsuoka Y; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Onagi A; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Tanji R; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Honda-Takinami R; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Hoshi S; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Koguchi T; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Sato Y; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Kataoka M; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Uemura M; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan., Igawa Y; Department of Urology, Nagano Prefectural Shinshu Medical Center, 1332 Suzaka, Nagano 382-8577, Japan., Kojima Y; Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 16; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 16.

Cyclophosphamide-induced Down-Regulation of Uroplakin II in the Mouse Urinary Bladder Epithelium is Prevented by S-Allyl Cysteine.

Autor: Abdi SA; Department of Medical Elementology & Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India.; Department of Pharmacology, Jamia Hamdard (Hamdard University), New Delhi, India.; Faculty of Interdisciplinary Sciences and Technology, Jamia Hamdard, New Delhi, India., Najmi AK; Department of Pharmacology, Jamia Hamdard (Hamdard University), New Delhi, India., Raisuddin S; Department of Medical Elementology & Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India.

Publikováno v: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2016 Dec; Vol. 119 (6), pp. 598-603. Date of Electronic Publication: 2016 Jul 21.

Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites.

Autor: Tajima S; Department of Pathology, Fujieda Municipal General Hospital, Shizuoka 426-8677, Japan., Koda K; Department of Pathology, Fujieda Municipal General Hospital, Shizuoka 426-8677, Japan.

Publikováno v: Disease markers [Dis Markers] 2016; Vol. 2016, pp. 2940496. Date of Electronic Publication: 2016 May 26.

Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.

Autor: Li W; From the Departments of Pathology and., Liang Y; From the Departments of Pathology and., Deavers MT; From the Departments of Pathology and., Kamat AM; Urology, University of Texas MD Anderson Cancer Center, Houston., Matin SF; Urology, University of Texas MD Anderson Cancer Center, Houston., Dinney CP; Urology, University of Texas MD Anderson Cancer Center, Houston., Czerniak B; From the Departments of Pathology and., Guo CC; From the Departments of Pathology and ccguo@mdanderson.org.

Publikováno v: American journal of clinical pathology [Am J Clin Pathol] 2014 Dec; Vol. 142 (6), pp. 864-71.